ABBV shares surge with Skyrizi and Rinvoq sales offsetting Humira decline: weekly forecast

Traders Union
All News
Financial News
AbbVie gains 6.97% this week

Highlights

AbbVie has rebounded 6.97% over the past week, closing near recent highs as short-term buyers emerge.
Technical momentum remains mixed, with oversold oscillators suggesting potential opportunities but most indicators still signaling seller dominance.
Expected range for the coming week is $205.99 to $219.93, with higher risk of decline and limited probability of further gains.

Earnings beat and drug demand drive positive sentiment over the week

AbbVie reported robust financial results for the first quarter of 2026, with net revenues rising 12.4% year-on-year to $15 billion and adjusted EPS of $2.65, exceeding analyst expectations. The performance was led by high demand for Skyrizi and Rinvoq, which generated over $6.6 billion in sales and offset declining Humira revenues. The company raised its full-year adjusted EPS guidance and highlighted positive phase 1 results for ABBV-295 as well as a $1.4 billion investment in a new manufacturing campus in North Carolina.

Momentum doubts persist as strong rally faces mixed technical signals

On the weekly chart, ABBV has rallied sharply but remains below the MA-20 ($218.35) while staying above both the MA-50 ($212.92) and MA-200 ($176.20), confirming sustained long-term support but unresolved medium-term weakness. Key resistance lies at $219.93, and short-term support aligns with $205.99. While Stochastic RSI signals a strong buy and CCI points to oversold conditions, both MACD and RSI remain bearish, ADX trend strength is weak, and Bull/Bear Power is still deep in oversold territory, reflecting uncertainty in momentum despite the bounce.

Sideways range favored next week as upside lacks technical support

For the next 5 trading days, ABBV is expected to remain in a sideways range between $205.99 and $219.93, reflecting ongoing mixed technical signals from the weekly timeframe. The probability of further upside is low (under 20%), given the lack of buy signals from major momentum indicators. A break above $220 could open the way for renewed bullish momentum, while a drop below $206 would likely lead to further declines toward previous support areas.

Earlier, analysts noted that AbbVie remained under sustained selling pressure, with technical indicators signaling a persistent bearish bias. While the latest surge reflects improved fundamentals and a sharp short-term rebound, momentum indicators continue to show uncertainty, making a sustained move above $220 the key signal to watch for any renewed bullish trend.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.